You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 3, 2025

Details for Patent: 7,674,776


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,674,776
Title:Combination therapy for effecting weight loss and treating obesity
Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Inventor(s): Najarian; Thomas (Los Osos, CA)
Assignee: Vivus, Inc. (Mountain View, CA)
Application Number:11/385,233
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,674,776
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use; Formulation;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,674,776

Introduction

United States Patent 7,674,776, hereafter referred to as the '776 patent, is a significant patent in the pharmaceutical sector, particularly related to weight loss treatments. This analysis will delve into the details of the patent's scope, claims, and the broader patent landscape in which it operates.

Overview of the Patent

The '776 patent is one of several patents held by Vivus, Inc., a pharmaceutical company, related to the drug Qsymia (phentermine and topiramate extended-release). This patent is part of a family of patents that cover various aspects of the drug's formulation, dosage, and method of use.

Claim Construction

Claim construction is a critical aspect of patent law, as it determines the scope of the invention and what is protected by the patent. For the '776 patent, the claims are centered around a specific formulation and method of use for a weight loss treatment.

Claim Language

The claims in the '776 patent, such as claims 10-17, 25, 26, and 42, describe a unit dosage form for weight loss that includes a combination of phentermine and topiramate. The claim language is precise, specifying the dosage form, the active ingredients, and the conditions under which the treatment is administered[2].

Prosecution History

The prosecution history of the patent, including the interactions between the patent applicant and the USPTO, is crucial in understanding the intended scope of the claims. For instance, any statements made during the prosecution that narrow the scope of the claims can limit their interpretation. In the case of the '776 patent, Actavis argued that the prosecution history indicated the patentee intended to narrow the scope to phentermine, despite initial broader claims[2].

Patentability Requirements

For a patent to be valid, it must meet several patentability requirements.

Eligible Subject Matter

The '776 patent must fall within the eligible subject matter as defined by the Patent Act. This includes "any new and useful process, machine, manufacture, or composition of matter, or any improvement thereof." The Supreme Court has clarified that laws of nature, natural phenomena, and abstract ideas are not patentable[1].

Novelty Requirement

The invention must be novel, meaning it must not have been previously disclosed in the prior art. The '776 patent's claims must be new and not anticipated by existing knowledge at the time of the patent application[1].

Nonobviousness Requirement

The invention must also be nonobvious, meaning it must be significantly different from existing knowledge and not an obvious combination of prior art. The '776 patent's unique combination of phentermine and topiramate and its specific dosage form would need to meet this criterion[1].

Post-Grant Proceedings

The Leahy-Smith America Invents Act (AIA) introduced several post-grant proceedings that allow for the challenge of patent validity, including Inter Partes Review (IPR) and Post-Grant Review (PGR). These proceedings, administered by the Patent Trial and Appeal Board (PTAB), provide a faster and less expensive alternative to judicial proceedings for challenging patent validity[1].

Current Debates and Reforms

There are ongoing debates and proposed reforms related to PTAB and post-grant proceedings. Issues such as standing, burdens of proof, discretionary institution of IPRs, claim construction, and the role of the USPTO Director in reviewing PTAB decisions are under scrutiny. These debates can impact the validity and enforcement of patents like the '776 patent[1].

Patent Landscape

The '776 patent operates within a complex patent landscape, particularly in the pharmaceutical sector. The Global Dossier service provided by the USPTO allows users to see the patent family for a specific application, including related applications filed at participating IP Offices. This can help in understanding the broader patent landscape and potential challenges or opportunities[4].

Economic and Research Implications

The Patent Claims Research Dataset by the USPTO provides detailed information on claims from U.S. patents, including those related to pharmaceuticals. This dataset can be used to analyze trends and measurements of patent scope, which is crucial for understanding the economic implications of patents like the '776 patent[3].

Small Claims Patent Court

There have been discussions and studies on the feasibility of a small claims patent court, which could impact how smaller entities navigate patent disputes. This could potentially affect the enforcement and defense strategies for patents like the '776 patent, especially for smaller pharmaceutical companies[5].

Key Takeaways

  • Claim Construction: The '776 patent's claims are specific and centered around a unique formulation and method of use for a weight loss treatment.
  • Patentability Requirements: The patent must meet novelty, nonobviousness, and eligible subject matter requirements.
  • Post-Grant Proceedings: The AIA's post-grant proceedings provide mechanisms for challenging patent validity.
  • Current Debates: Ongoing debates and reforms related to PTAB and post-grant proceedings can impact patent validity and enforcement.
  • Patent Landscape: The '776 patent is part of a complex patent landscape, with tools like the Global Dossier aiding in its navigation.
  • Economic Implications: The patent's scope and validity have significant economic implications, especially in the pharmaceutical sector.

FAQs

What is the main subject matter of United States Patent 7,674,776?

The main subject matter of the '776 patent is a unit dosage form for weight loss, specifically a combination of phentermine and topiramate.

How does the prosecution history affect the interpretation of the '776 patent's claims?

The prosecution history can limit the scope of the claims if there are clear and unmistakable statements made during the prosecution that narrow the invention's scope.

What are the key patentability requirements that the '776 patent must meet?

The '776 patent must meet the requirements of eligible subject matter, novelty, and nonobviousness.

How do post-grant proceedings like IPR and PGR impact the validity of the '776 patent?

Post-grant proceedings provide a mechanism for challenging the validity of the '776 patent, offering a faster and less expensive alternative to judicial proceedings.

What is the significance of the Global Dossier in understanding the patent landscape of the '776 patent?

The Global Dossier allows users to see related applications filed at participating IP Offices, providing a comprehensive view of the patent family and broader patent landscape.

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Casetext, "Vivus, Inc. v. Actavis Labs. FL, Inc."
  3. USPTO, "Patent Claims Research Dataset."
  4. USPTO, "Search for patents."
  5. Administrative Conference of the United States, "U.S. Patent Small Claims Court."

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,674,776

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 7,674,776

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2008262566 ⤷  Subscribe
Australia 5489600 ⤷  Subscribe
Australia 770068 ⤷  Subscribe
Austria 369126 ⤷  Subscribe
Canada 2377330 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.